Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Biography
Dr. Binkley is a radiation oncologist specializing in lymphoma treatment and an assistant professor in the Stanford University School of Medicine Department of Radiation Oncology.
His clinical expertise includes stereotactic ablative radiotherapy (SABR), total lymphoid and total body irradiation, and intensity modulated radiation therapy (IMRT).
For each patient, Dr. Binkley develops a personalized, comprehensive, and compassionate care plan. His goals are to improve both health and quality of life.
Dr. Binkley has conducted extensive research to advance cancer treatment. In his post-doctoral fellowship at Stanford, he studied the use of genomic signatures to predict response to radiotherapy. His current clinical and laboratory research seek to identify prognostic and predictive clinical, radiographic, and genomic factors to inform individualized treatment strategies.
He has co-authored articles on his research discoveries published in Cancer Discovery, Blood, the International Journal of Radiation Oncology*Biology*Physics, and elsewhere. Topics have included innovations in the treatment of lymphoma and lung cancer.
He also has made invited presentations to colleagues at national and international conferences. He has presented the latest findings on radiation therapy for lung cancer and lymphoma at meetings of the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and International Conference on Malignant Lymphoma (ICML).
Honors for Dr. Binkley include the Malcolm A. Bagshaw Award for leadership and outstanding scientific achievement. This award is named for a pioneer in radiation therapy and former chair of the Departments of Radiology and Radiation Oncology at Stanford University School of Medicine.
Dr. Binkley is a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, and American Association for Cancer Research. He is a founding member of the Global nLPHL One Working (GLOW) Working Group, an international collaboration studying nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in children and adults.
His clinical expertise includes stereotactic ablative radiotherapy (SABR), total lymphoid and total body irradiation, and intensity modulated radiation therapy (IMRT).
For each patient, Dr. Binkley develops a personalized, comprehensive, and compassionate care plan. His goals are to improve both health and quality of life.
Dr. Binkley has conducted extensive research to advance cancer treatment. In his post-doctoral fellowship at Stanford, he studied the use of genomic signatures to predict response to radiotherapy. His current clinical and laboratory research seek to identify prognostic and predictive clinical, radiographic, and genomic factors to inform individualized treatment strategies.
He has co-authored articles on his research discoveries published in Cancer Discovery, Blood, the International Journal of Radiation Oncology*Biology*Physics, and elsewhere. Topics have included innovations in the treatment of lymphoma and lung cancer.
He also has made invited presentations to colleagues at national and international conferences. He has presented the latest findings on radiation therapy for lung cancer and lymphoma at meetings of the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and International Conference on Malignant Lymphoma (ICML).
Honors for Dr. Binkley include the Malcolm A. Bagshaw Award for leadership and outstanding scientific achievement. This award is named for a pioneer in radiation therapy and former chair of the Departments of Radiology and Radiation Oncology at Stanford University School of Medicine.
Dr. Binkley is a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, and American Association for Cancer Research. He is a founding member of the Global nLPHL One Working (GLOW) Working Group, an international collaboration studying nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in children and adults.
View Full Biography »
Professional Summary
Education & Certifications
- Board Certification: American Board of Radiology, Radiation Oncology (2022)
- Residency: Stanford University Radiation Oncology Residency (2021) CA
- Internship: Santa Clara Valley Medical Center Internal Medicine Residency (2017) CA
- Medical Education: Stanford University School of Medicine (2016) CA
Publications
-
Lung Volume Reduction After Stereotactic Ablative Radiation Therapy of Lung Tumors: Potential Application to Emphysema
Binkley, M. S., Shrager, J. B., Leung, A. N., Popat, R., Trakul, N., Atwood, T. F., … Loo, B. W. (2014). Lung Volume Reduction After Stereotactic Ablative Radiation Therapy of Lung Tumors: Potential Application to Emphysema. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90(1), 216–23. -
Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors
Chaudhuri, A. A., Tang, C., Binkley, M. S., Jin, M., Wynne, J. F., von Eyben, R., … Diehn, M. (2015). Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. LUNG CANCER, 89(1), 50–56. -
Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
Binkley, M. S., Trakul, N., Jacobs, L. R., von Eyben, R., Quynh-Thu Le, Q. T., Maxim, P. G., … Diehn, M. (2015). Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 92(5), 1044–52. -
Lung volume reduction after stereotactic ablative radiation therapy of lung tumors: potential application to emphysema.
Binkley, M. S., Shrager, J. B., Leung, A. N., Popat, R., Trakul, N., Atwood, T. F., … Loo, B. W. (2014). Lung volume reduction after stereotactic ablative radiation therapy of lung tumors: potential application to emphysema. International Journal of Radiation Oncology, Biology, Physics, 90(1), 216–23. -
Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.
Chaudhuri, A. A., Binkley, M. S., Osmundson, E. C., Alizadeh, A. A., & Diehn, M. (2015). Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. Seminars in Radiation Oncology, 25(4), 305–12. -
Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery
Hiniker, S. M., Modlin, L. A., Choi, C. Y., Atalar, B., Seiger, K., Binkley, M. S., … Soltys, S. G. (2016). Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery. SEMINARS IN RADIATION ONCOLOGY, 26(2), 97–104. -
Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation.
Binkley, M. S., Hiniker, S. M., Chaudhuri, A., Maxim, P. G., Diehn, M., Loo, B. W., & Shultz, D. B. (2016). Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation. International Journal of Radiation Oncology, Biology, Physics, 94(4), 808–15. -
Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors.
Binkley, M. S., Shrager, J. B., Chaudhuri, A., Popat, R., Maxim, P. G., Shultz, D. B., … Loo, B. W. (2016). Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors. Radiation Oncology , 11(1), 40-? -
Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors
Binkley, M. S., Shrager, J. B., Chaudhuri, A., Popat, R., Maxim, P. G., Shultz, D. B., … Loo, B. W. (2016). Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors. RADIATION ONCOLOGY, 11. -
A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy
Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mittra, E. S., Advani, R. H., & Hoppe, R. T. (2016). A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. LEUKEMIA & LYMPHOMA, 57(3), 604–8. -
A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mittra, E. S., Advani, R. H., & Hoppe, R. T. (2016). A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leukemia & Lymphoma, 57(3), 604–8. -
Severe Chest Wall Toxicity From Cryoablation in the Setting of Prior Stereotactic Ablative Radiotherapy.
Chaudhuri, A. A., Binkley, M. S., Aggarwal, S., Qian, Y., Carter, J. N., Shah, R., & Loo, B. W. (2016). Severe Chest Wall Toxicity From Cryoablation in the Setting of Prior Stereotactic Ablative Radiotherapy. Cure¯Us, 8(2). -
Partial orbit irradiation achieves excellent outcomes for primary orbital lymphoma.
Binkley, M. S., Hiniker, S. M., Donaldson, S. S., & Hoppe, R. T. (2016). Partial orbit irradiation achieves excellent outcomes for primary orbital lymphoma. Practical Radiation Oncology, 6(4), 255–61. -
Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).
Chaudhuri, A. A., Binkley, M. S., Rigdon, J., Carter, J. N., Aggarwal, S., Dudley, S. A., … Guo, H. H. (2016). Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). Radiotherapy and Oncology , 119(3), 454–60. -
Tracheal Diverticulum Following Paratracheal Hypofractionated Radiotherapy in the Setting of Prior and Subsequent Bevacizumab.
Chaudhuri, A. A., Chen, J. J., Carter, J. N., Binkley, M. S., Kumar, K. A., Dudley, S. A., … Loo, B. W. (2016). Tracheal Diverticulum Following Paratracheal Hypofractionated Radiotherapy in the Setting of Prior and Subsequent Bevacizumab. Cure¯Us, 8(4). -
Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung.
Binkley, M. S., King, M. T., Shrager, J. B., Bush, K., Chaudhuri, A. A., Popat, R., … Loo, B. W. (2017). Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung. Radiotherapy and Oncology , 123(2), 270–75. -
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery. -
Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 98(2), E4. -
18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy.
Qian, Y., Von Eyben, R., Liu, Y., Chin, F. T., Miao, Z., Apte, S., … Loo, B. W. (2018). 18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics. -
18F-EF5 Pet-Based Imageable Hypoxia Predicts for Local Control in Tumors Treated With Conformal Radiotherapy
Qian, Y., Liu, Y., Von Eyben, R., Carter, J. N., Pollom, E. L., Harris, J. P., … Loo, B. W. (2018). 18F-EF5 Pet-Based Imageable Hypoxia Predicts for Local Control in Tumors Treated With Conformal Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG.
Brady, J. L., Binkley, M. S., Hajj, C., Chelius, M., Chau, K., Balogh, A., … Mikhaeel, N. G. (2018). Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood. -
Salvage treatment and survival for relapsed follicular lymphoma following primary radiotherapy: A collaborative study on behalf of ILROG.
Binkley, M. S., Brady, J. L., Hajj, C., Chelius, M., Chau, K., Balogh, A., … Hoppe, R. T. (2019). Salvage treatment and survival for relapsed follicular lymphoma following primary radiotherapy: A collaborative study on behalf of ILROG. International Journal of Radiation Oncology, Biology, Physics. -
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Chin, R.-I. I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., … Chaudhuri, A. A. (2019). Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). Molecular Diagnosis & Therapy. -
Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery.
Hiniker, S. M., Modlin, L. A., Choi, C. Y., Atalar, B., Seiger, K., Binkley, M. S., … Soltys, S. G. (2016). Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery. Seminars in Radiation Oncology, 26(2), 97–104. -
Tracheal Diverticulum Following Paratracheal Hypofractionated Radiotherapy in the Setting of Prior and Subsequent Bevacizumab
Chaudhuri, A. A., Chen, J. J., Carter, J. N., Binkley, M. S., Kumar, K. A., Dudley, S. A., … Loo, B. W. (2016). Tracheal Diverticulum Following Paratracheal Hypofractionated Radiotherapy in the Setting of Prior and Subsequent Bevacizumab. CUREUS, 8(4). -
F-18-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy
Qian, Y., Von Eyben, R., Liu, Y., Chin, F. T., Miao, Z., Apte, S., … Loo Jr, B. W. (2018). F-18-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102(4), 1183–92. -
Severe Chest Wall Toxicity From Cryoablation in the Setting of Prior Stereotactic Ablative Radiotherapy
Chaudhuri, A. A., Binkley, M. S., Aggarwal, S., Qian, Y., Carter, J. N., Shah, R., & Loo, B. W. (2016). Severe Chest Wall Toxicity From Cryoablation in the Setting of Prior Stereotactic Ablative Radiotherapy. CUREUS, 8(2). -
Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG
Binkley, M. S., Brady, J. L., Hajj, C., Chelius, M., Chau, K., Balogh, A., … Hoppe, R. T. (2019). Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 104(3), 522–29. -
Detection of Solid Tumor Molecular Residual Disease(MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., … Chaudhuri, A. A. (2019). Detection of Solid Tumor Molecular Residual Disease(MRD) Using Circulating Tumor DNA (ctDNA). MOLECULAR DIAGNOSIS & THERAPY, 23(3), 311–31. -
Definitive radiotherapy for localized follicular lymphoma staged by F-18-FDG PET-CT: a collaborative study by ILROG
Brady, J. L., Binkley, M. S., Hajj, C., Chelius, M., Chau, K., Balogh, A., … Mikhaeel, G. (2019). Definitive radiotherapy for localized follicular lymphoma staged by F-18-FDG PET-CT: a collaborative study by ILROG. BLOOD, 133(3), 237–45. -
Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG.
Binkley, M. S., Rauf, M. S., Milgrom, S. A., Pinnix, C. C., Tsang, R. W., Dickinson, M., … Hoppe, R. T. (2020). Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG. Blood. -
Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume.
Binkley, M. S., Koenig, J. L., Kashyap, M., Xiang, M., Liu, Y., Sodji, Q., … Gensheimer, M. F. (2020). Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume. Radiation Oncology (London, England), 15(1), 114. -
KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., … Diehn, M. (2020). KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.
Binkley, M. S., Jeon, Y.-J. J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., … Diehn, M. (2020). KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. Cancer Discovery. -
Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy.
Binkley, M. S., Hiniker, S. M., Younes, S., Yoo, C., Wignarajah, A., Jin, M., … Hoppe, R. T. (2021). Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy. Leukemia & Lymphoma, 1–15. -
Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma.
Haebe, S. E., Shree, T., Sathe, A., Day, G., Czerwinski, D. K., Grimes, S., … Levy, R. (2021). Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma. Blood. -
Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., … Diehn, M. (2021). Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma
Hui, C., Wu, Y. (F., Liu, K., Sandhu, N., Blomain, E., Binkley, M., … Pollom, E. (2021). Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Radiotherapy for Management of Brain Metastases from Thyroid Cancer: A National Cancer Database Study
Blomain, E., Binkley, M., Giao, D., Churilla, T., Soltys, S., & Pollom, E. (2021). Radiotherapy for Management of Brain Metastases from Thyroid Cancer: A National Cancer Database Study. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Acute and Late Esophageal Toxicity Following Stereotactic Ablative Radiotherapy to Thoracic Tumors near or Abutting the Esophagus.
Sodji, Q. H., Ko, R., von Eyben, R., Owen, S. G., Capaldi, D. P., Bush, K., … Loo, B. W. (1800). Acute and Late Esophageal Toxicity Following Stereotactic Ablative Radiotherapy to Thoracic Tumors near or Abutting the Esophagus. International Journal of Radiation Oncology, Biology, Physics. -
RADIOTHERAPY FOR BRAIN METASTASES FROM THYROID CANCER: A RETROSPECTIVE COHORT STUDY
Blomain, E., Berta, S., Hug, N., Giao, D., Meola, A., Binkley, M., … Pollom, E. (2021). RADIOTHERAPY FOR BRAIN METASTASES FROM THYROID CANCER: A RETROSPECTIVE COHORT STUDY. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
Radiotherapy for brain metastases from thyroid cancer: an institutional and national retrospective cohort study.
Blomain, E. S., Berta, S., Hug, N. F., Giao, D. M., Meola, A., Binkley, M. S., … Pollom, E. L. (2022). Radiotherapy for brain metastases from thyroid cancer: an institutional and national retrospective cohort study. Thyroid : Official Journal of the American Thyroid Association. -
Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW).
Lo, A. C., Major, A., Super, L., Appel, B., Shankar, A., Constine, L. S., … Flerlage, J. (2022). Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW). Leukemia & Lymphoma, 1–4. -
Inferring gene expression from cell-free DNA fragmentation profiles.
Esfahani, M. S., Hamilton, E. G., Mehrmohamadi, M., Nabet, B. Y., Alig, S. K., King, D. A., … Alizadeh, A. A. (2022). Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology. -
Digital Spatial Profiling Reveals Spatial Heterogeneity in Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Rojansky, R., Younes, S., Subramanian, A., Binkley, M., & Natkunam, Y. (2022). Digital Spatial Profiling Reveals Spatial Heterogeneity in Nodular Lymphocyte-Predominant Hodgkin Lymphoma. LABORATORY INVESTIGATION. SPRINGERNATURE. -
Digital Spatial Profiling Reveals Spatial Heterogeneity in Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Rojansky, R., Younes, S., Subramanian, A., Binkley, M., & Natkunam, Y. (2022). Digital Spatial Profiling Reveals Spatial Heterogeneity in Nodular Lymphocyte-Predominant Hodgkin Lymphoma. MODERN PATHOLOGY. SPRINGERNATURE. -
The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer.
Sodji, Q. H., Nambiar, D. K., Viswanathan, V., von Eyben, R., Colburg, D., Binkley, M. S., … Giaccia, A. J. (2022). The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer. Cancer Research Communications, 2(7), 725–738. -
Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma.
Binkley, M. S. (2022). Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma. British Journal of Haematology. -
Analysis of Metabolic Tumor Volume in Patients Undergoing Radiotherapy Prior to or After CAR-T Therapy for Relapsed/refractory Aggressive B Cell Lymphoma
Marar, M., Hiniker, S., Hoppe, R., & Binkley, M. (2022). Analysis of Metabolic Tumor Volume in Patients Undergoing Radiotherapy Prior to or After CAR-T Therapy for Relapsed/refractory Aggressive B Cell Lymphoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma.
Hui, C., Wu, Y. F., Liu, K., Sandhu, N., Blomain, E., Binkley, M. S., … Pollom, E. (2022). Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma. Cureus, 14(11), e31838. -
STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer.
Katipally, R. R., Spurr, L. F., Gutiontov, S. I., Turchan, W. T., Connell, P., Juloori, A., … Pitroda, S. P. (2023). STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precision Oncology, 7, e2200273. -
Investigating and modeling positron emission tomography factors associated with large cell transformation from low-grade lymphomas.
Obeid, J.-P. P., Hiniker, S. M., Schroers-Martin, J., Guo, H. H., No, H. J., Moding, E. J., … Binkley, M. S. (2023). Investigating and modeling positron emission tomography factors associated with large cell transformation from low-grade lymphomas. EJHaem, 4(1), 90–99. -
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., … Arai, S. (2023). Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. -
Investigating Metabolic Response after CAR-T Therapy and Bridging Radiotherapy for Relapsed/Refractory B-Cell Lymphoma
Marar, M., Hiniker, S., Hoppe, R., & Binkley, M. (2022). Investigating Metabolic Response after CAR-T Therapy and Bridging Radiotherapy for Relapsed/Refractory B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley, M. S., & Advani, R. H. (2023). Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. -
Spatial phenotyping of Nodular Lymphocyte Predominant Hodgkin Lymphoma and T-cell/Histiocyte-Rich Large B-cell Lymphoma using PhenoCycler (formerly CODEX)
Younes, S., Subramanian, A., Khan, A., Zhao, S., Binkley, M., & Natkunam, Y. (2023). Spatial phenotyping of Nodular Lymphocyte Predominant Hodgkin Lymphoma and T-cell/Histiocyte-Rich Large B-cell Lymphoma using PhenoCycler (formerly CODEX). LABORATORY INVESTIGATION. ELSEVIER SCIENCE INC. -
Investigating the tissue specificity and prognostic impact of cis-regulatory cancer risk variants.
Subramanian, A., Su, S., Moding, E. J., & Binkley, M. S. (2023). Investigating the tissue specificity and prognostic impact of cis-regulatory cancer risk variants. Human Genetics. -
The pathobiology of select adolescent young adult lymphomas.
Steidl, C., Kridel, R., Binkley, M., Morton, L. M., & Chadburn, A. (2023). The pathobiology of select adolescent young adult lymphomas. EJHaem, 4(4), 892–901. -
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.
Alig, S. K., Esfahani, M. S., Garofalo, A., Li, M. Y., Rossi, C., Flerlage, T., … Alizadeh, A. A. (2023). Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling. Nature. -
Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
No, H. J., Guo, F. B., Park, N. J.-I., Kastelowitz, N., Rhee, J.-W. W., Clark, D. E., … Binkley, M. S. (2023). Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer. JACC. CardioOncology, 5(6), 775–787. -
Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.
Lee, D., Goyal, A., Wang, W. L., Ananth, S., Lau, E., Binkley, M. S., … Dahiya, S. (2024). Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient. EJHaem, 5(1), 153–156. -
Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods
Alig, S. K., Esfahani, M. S., Garofalo, A., Li, M. Y., Rossi, C., Flerlage, T., … Alizadeh, A. A. (2023). Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods. BLOOD. AMER SOC HEMATOLOGY. -
Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
Bharadwaj, S., Lau, E., Hashmi, A., Hamilton, M. P., Jensen, A., Goyal, A., … Dahiya, S. (2023). Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY. -
Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification
Mutter, J. A., Esfahani, M. S., Schroers-Martin, J., Alig, S. K., Hamilton, M. P., Sworder, B. J., … Alizadeh, A. A. (2023). Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification. BLOOD. AMER SOC HEMATOLOGY.
Practice Locations
Lymphoma Program Palo Alto, CA
Palo Alto, CA
Lymphoma Program
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur Palo Alto, CA
Palo Alto, CA
CyberKnife Stereotactic Radiosurgery Program at 875 Blake Wilbur
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Radiation Oncology at Blake Wilbur Building Palo Alto, CA
Palo Alto, CA
Radiation Oncology at Blake Wilbur Building
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(23 reviews)
Very nice , and concerned about my convenience for future in person visits
Very personable and knowledgeable. Seem to be truly interested and invested in my treatment
Dr. Brinkley was personal and answered all of our questions so that we were able to comprehend and fully understand the process of radiation treatment.
Thanks very much for your service and care, Dr. Binkley! I cannot thank you enough for your support during the difficult time I was getting the treatment. I am grateful to you!
sharp, personable, relatable
He was very friendly and informative. We really appreciated his manner and his wisdom.
He’s alright.
He is an excellent communicator and it is a pleasure to have him as part of my medical 'team' at Stanford!!
He also oversaw a rather technical radiation treatment that has been successful to resolving my recurrent cancer.
I’m very grateful I have him as my doctor. He and his team are indescribably important people in my life
Dr Binkley is an excellent physician with an excellent bedside manner. He asks relevant questions and explains my condition and treatment in a clear understandable manner. He is thorough about explaining the current treatment and possible side effects. He is also looking to the future about further treatments including those provided by my oncologist /hematologist. He is very knowledgeable about my disease and the up to date current array of treatments outside of his radiation oncology specialty. I would recommend him highly to family or friends who are considering radiation therapy.
Dr Binkley explained everything to me and was very thorough
Dr Binkley is a caring physician, excellent clinician, and great communicator . I am grateful to have him as my radiation oncologist.
Very nice great personality
Explains treatment clearly so that I felt confident in his care.
He seems confident that this treatment will work.
Michael was very clear on what he was telling me on what is next for me.
Outstanding.
Good overall experience.
Br Brinkley answered all my concerns.
Always clear and helpful. Puts me at ease.
Great doctor!
Thorough with good manner to him
He is very professional
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records